Hetzel-Sesterheim M, Schnabel K, Nestle U, Hamann G, Berberich W
Abteilung für Strahlentherapie, Universitätskliniken Homburg/Saar.
Strahlenther Onkol. 1996 Apr;172(4):198-204.
In the last years many therapeutic attempts were made to improve the poor prognosis of primary cerebral non Hodgkin's lymphoma. The aim of this study was to report on own experiences concerning this rare disease.
In 1986 to 1994 26 patients were treated for primary cerebral non Hodgkin's lymphoma. 15% were HIV-positive. High-grade non-Hodgkin's lymphomas were diagnosed in 62%. 46% of all cases showed multiple lesions. 23% of our patients received a dose less than 25.5 Gy, 27% received 37.5 Gy (whole brain) and 39% were treated with 51 Gy (37.5 Gy whole brain and 13.5 Gy boost dose). Radiation technique included regular and irregular fields (single dose: 1.5 Gy).
62% of patients achieved a complete or partial remission directly after irradiation, in 4% no change or progression was seen. 31% could not be examined due to their bad status or death. The mean follow-up time for all patients was 19.6 months, the median survival was 3.6 months. The 1-year-survival rate was 41%, 3-year survival rate was 28%. Patients who received a tumor dose of 51 Gy had better survival times in comparison to patients who received less (p = 0.01). Prognostic parameters (Cox regression analysis) were: tumor dose, grading and local result after irradiation. The Karnofsky performance status was not an independent parameter (p = 0.12). Side effects were low. Long-term survivors had relatively good quality of life.
Taking into consideration the small numbers of patients in all studies all results or conclusions have to be made with great reservations. Despite the high proportion of HIV-positive patients our results are in compliance with other authors using similar therapy protocols. Reports dealing with combined radio-chemotherapy have published good results concerning survival time. But long-term morbidity due to these protocols needs further investigation and has to be awaited.
在过去几年中,人们进行了许多治疗尝试以改善原发性脑非霍奇金淋巴瘤的不良预后。本研究的目的是报告关于这种罕见疾病的自身经验。
1986年至1994年期间,26例患者接受了原发性脑非霍奇金淋巴瘤的治疗。15%为HIV阳性。62%被诊断为高级别非霍奇金淋巴瘤。所有病例中有46%显示有多个病灶。23%的患者接受的剂量小于25.5 Gy,27%接受37.5 Gy(全脑),39%接受51 Gy(37.5 Gy全脑加13.5 Gy推量剂量)治疗。放疗技术包括常规和不规则野(单次剂量:1.5 Gy)。
62%的患者在放疗后直接达到完全或部分缓解,4%未见变化或病情进展。31%因病情不佳或死亡无法进行检查。所有患者的平均随访时间为19.6个月,中位生存期为3.6个月。1年生存率为41%,3年生存率为28%。接受51 Gy肿瘤剂量的患者与接受较低剂量的患者相比生存期更长(p = 0.01)。预后参数(Cox回归分析)为:肿瘤剂量、分级和放疗后的局部结果。卡诺夫斯基功能状态不是一个独立参数(p = 0.12)。副作用较低。长期存活者的生活质量相对较好。
考虑到所有研究中的患者数量较少,所有结果或结论都必须非常谨慎地得出。尽管HIV阳性患者比例较高,但我们的结果与使用类似治疗方案的其他作者一致。关于联合放化疗的报告已发表了关于生存时间的良好结果。但这些方案导致的长期发病率需要进一步研究并有待观察。